PT - JOURNAL ARTICLE AU - XIAOYAN CAI AU - XIUYAN YANG AU - FAN LIAN AU - XIAOJUN LIN AU - MING LIANG AU - JIANWEN LI AU - XIAOHUI CHEN AU - LIUQING LIANG AU - SHUGUANG QIN AU - JUNZHOU FU TI - Correlation Between Serum Anti-C1q Antibody Levels and Renal Pathological Characteristics and Prognostic Significance of Anti-C1q Antibody in Lupus Nephritis AID - 10.3899/jrheum.090779 DP - 2010 Apr 01 TA - The Journal of Rheumatology PG - 759--765 VI - 37 IP - 4 4099 - http://www.jrheum.org/content/37/4/759.short 4100 - http://www.jrheum.org/content/37/4/759.full SO - J Rheumatol2010 Apr 01; 37 AB - Objective. To investigate the relationship between serum anti-C1q antibody levels and renal pathological characteristics in lupus nephritis as well as the prognostic significance of serum anti-C1q antibody. Methods. Seventy-three patients with biopsy-proven lupus nephritis were enrolled. Anti-C1q antibody was measured in serum samples taken within 7 days before renal biopsy and remeasured at the end of the first and the third month after treatment. All patients were followed at least once a month for 3 months. A cross-sectional study analyzed the relationship between serum anti-C1q antibody levels and renal histopathology and nephritic activity, while a longitudinal study evaluated the prognostic significance of anti-C1q antibody levels in lupus nephritis. Results. Fifty-eight of 73 patients (79.5%) were reported as having positive baseline serum anti-C1q antibody, with a mean level of 95.3 (± 55.2) U/ml. Significant differences were found in serum anti-C1q antibody levels between each World Health Organization (WHO) classification of lupus nephritis. The serum anti-C1q antibody level of WHO class IV was the highest. Serum anti-C1q antibody was positively correlated with the active and chronic indices in renal pathology. Patients with persistent high levels or increased titers of serum anti-C1q antibody tended to develop delayed remission in nephropathy. Serum anti-C1q antibody levels before and after treatment were relevant to renal remission, but serum anti-C1q antibody at the end of the third month after treatment was a stronger predictor for the prognosis after adjustment in the Cox’s proportional hazards regression model. Conclusion. Serum anti-C1q antibody is a valuable noninvasive biological marker for evaluation of renal involvement and lupus prognosis.